7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-N-(3-pyrrolidin-1-ylpropyl)-1H-1,5-naphthyridine-3-carboxamide | 1417659-18-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-N-(3-pyrrolidin-1-ylpropyl)-1H-1,5-naphthyridine-3-carboxamide
• CAS: 1417659-18-7
• 化学式: C₂₃H₂₅FN₄O₃
• 分子量: 424.475
• InChiKey: IGVFBVBNNDZUPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  94.6
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-氨基-5-(4-氟苄基)-2-吡啶羧酸甲酯 在 sodium ethanolate 作用下， 以 乙醇 、 1,2-二氯乙烷 为溶剂， 生成 7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-N-(3-pyrrolidin-1-ylpropyl)-1H-1,5-naphthyridine-3-carboxamide
  参考文献：
  名称：

  Naphthyridinone (NTD) integrase inhibitors: N1 Protio and methyl combination substituent effects with C3 amide groups

  摘要：

  Substituent effects of a series of N1 protio and methyl naphthyridinone HIV-1 integrase strand-transfer inhibitors has been explored. The effects of combinations of the N1 substituent and C3 amide groups was extensively studied to compare enzyme inhibition, antiviral activity and protein binding effects on potency. The impact of substitution on ligand efficiency was considered and several compounds were advanced into in vivo pharmacokinetic studies ultimately leading to the clinical candidate GSK364735. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.071

文献信息

• Naphthyridinone (NTD) integrase inhibitors: N1 Protio and methyl combination substituent effects with C3 amide groups
  作者：Brian A. Johns、Takashi Kawasuji、Jason G. Weatherhead、Eric E. Boros、James B. Thompson、Cecilia S. Koble、Edward P. Garvey、Scott A. Foster、Jerry L. Jeffrey、Tamio Fujiwara

  DOI：10.1016/j.bmcl.2012.11.071

  日期：2013.1

  Substituent effects of a series of N1 protio and methyl naphthyridinone HIV-1 integrase strand-transfer inhibitors has been explored. The effects of combinations of the N1 substituent and C3 amide groups was extensively studied to compare enzyme inhibition, antiviral activity and protein binding effects on potency. The impact of substitution on ligand efficiency was considered and several compounds were advanced into in vivo pharmacokinetic studies ultimately leading to the clinical candidate GSK364735. (C) 2012 Elsevier Ltd. All rights reserved.